PharmaSGP Holding SE: Annual General Meeting approves full distribution of
the Group's profit for 2023 following a successful business performance

EQS-News: PharmaSGP Holding SE / Key word(s): AGM/EGM
PharmaSGP Holding SE: Annual General Meeting approves full distribution of
the Group's profit for 2023 following a successful business performance

27.06.2024 / 09:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PharmaSGP Holding SE: Annual General Meeting approves full distribution of
the Group's profit for 2023 following a successful business performance

  * 89.74% of the share capital was represented; all agenda items were
    approved

  * Shareholders approve increased dividend distribution of EUR1.36 per
    dividend-bearing share

  * The appointment of Peter Gerckens as Chief Commercial Officer to the
    Management Board underscores PharmaSGP's growth ambitions

Gräfelfing, June 27, 2024 - German OTC pharmaceutical company PharmaSGP
Holding SE successfully held its Annual General Meeting 2024 in Munich
yesterday. This year's Annual General Meeting was held as an in-person event
for the first time since the IPO in 2020. 89.74% of the share capital was
represented. All agenda items were approved by the Annual General Meeting.

At the Annual General Meeting, the Management Board reported on the
successful business performance in 2023. For the first time in the company's
history, revenues exceeded the EUR100 million mark, amounting to EUR101.1
million in total and increasing by 17.8% compared to the previous year
(EUR85.8 million). Adjusted EBITDA also increased by 20.8% from EUR28.2 million
in 2022 to EUR34.1 million in the 2023 financial year. The adjusted EBITDA
margin thus improved year-on-year from 32.9% to 33.7%.

This year again, PharmaSGP shareholders will participate in this strong
business performance in the form of a full distribution of the Group's
profit for 2023. The dividend therefore amounts to EUR1.36 per
dividend-bearing share. The corresponding proposal was approved by the
Annual General Meeting with 100%.

PharmaSGP continued its dynamic business development in the first quarter of
2024 and is well on track for another year of profitable growth. The high
expectations for further business development are also underlined by the
appointment of Peter Gerckens to the Management Board, where he will hold
the newly created position of Chief Commercial Officer (CCO) from July 1,
2024. In his role as CCO, Peter Gerckens will be responsible for the
expansion of international markets, sales and new businesses at PharmaSGP.

CEO Natalie Weigand comments: "We can look back on an exceptionally
successful financial year, which is reflected not least in the distribution
of a highly attractive dividend. We want to continue to build on this in the
future. With the appointment of Peter Gerckens as Chief Commercial Officer,
we are gaining another expert for PharmaSGP who will make a significant
contribution to further accelerating our growth path." Michael Rudolf, CFO
of PharmaSGP, adds: "In 2023, we exceeded our forecast in terms of both
revenues and adjusted EBITDA and significantly outperformed the market. In
addition to our well-proven pan-European platform, PharmaSGP has a strong
financial profile in particular, which gives us the necessary leeway to
realize further growth and make optimal use of the potential of our business
model."

For the financial year 2024, revenues are expected to be in a range between
EUR107.0 million and EUR112.0 million. The Management Board expects adjusted
EBITDA to increase to between EUR35.0 million and EUR38.0 million. This
corresponds to an adjusted EBITDA margin of 32.7% to 33.9%.

The detailed voting results for the Annual General Meeting 2024 are
available for download on PharmaSGP's corporate website in the Investor
Relations / Annual General Meeting section.

CONTACT

cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio
of over-the-counter (OTC) pharmaceuticals and other healthcare products that
are marketed with a focus on the pharmacy distribution channel. These
products are mostly based on natural active pharmaceutical ingredients with
documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic
pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is
the market leader for systemic chemical-free pain remedies with its brand
families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain.
Furthermore, PharmaSGP also offers leading products against sexual weakness
and vertigo symptoms. Since introducing the first product from the current
product portfolio in 2012, PharmaSGP has successfully established its
business model in other European countries, including Austria, Italy,
Belgium, Spain and France. In September 2021, the product portfolio was
expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus
also strengthening or developing the indications pain and sleep disorder.
The sales territory was expanded to include Switzerland and Eastern Europe.
In 2023, PharmaSGP generated revenues of EUR101.1 million at an adjusted
EBITDA margin of 33.7%.

In order to further expand its competitive position, PharmaSGP plans to
increase the number of indications covered by PharmaSGP's product offering,
increase PharmaSGP's European footprint, and accelerate its growth strategy
especially by capitalizing on selected M&A opportunities.


---------------------------------------------------------------------------

27.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        PharmaSGP Holding SE
                   Lochhamer Schlag 1
                   82166 Gräfelfing
                   Germany
   E-mail:         ir@pharmasgp.com
   Internet:       https://pharmasgp.com
   ISIN:           DE000A2P4LJ5
   WKN:            A2P4LJ
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Munich, Tradegate Exchange
   EQS News ID:    1934065

End of News EQS News Service
---------------------------------------------------------------------------

1934065 27.06.2024 CET/CEST